In this Issue:
- Cardiovascular safety of testosterone replacement therapy
- The FGF21 analogue pegozafermin for severe hypertriglyceridaemia
- Zilebesiran, an RNA interference therapeutic agent for hypertension
- Phase 1 trial of antibody NI006 for depletion of cardiac transthyretin amyloid
- Atorvastatin for anthracycline-associated cardiac dysfunction
- Mortality trends after primary PCI for STEMI in Denmark
- Cost-effectiveness of vericiguat in patients with HFrEF
- Mineralocorticoid receptor antagonists are underutilised in patients with HFrEF
- Phenotyping coronary plaque in patients with premature coronary artery disease
- Stroke risk in women with AF